4//SEC Filing
Werner Milton H. 4
Accession 0000950170-25-007741
CIK 0001750149other
Filed
Jan 21, 7:00 PM ET
Accepted
Jan 22, 4:05 PM ET
Size
43.7 KB
Accession
0000950170-25-007741
Insider Transaction Report
Form 4
Werner Milton H.
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2025-01-21+3,643→ 3,643 totalExercise: $1.26Exp: 2025-11-01→ Common Stock (3,643 underlying) - Award
Stock Option (Right to Buy)
2025-01-21+3,643→ 3,643 totalExercise: $1.26Exp: 2026-11-01→ Common Stock (3,643 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-01-21−16,667→ 0 totalExercise: $60.00Exp: 2030-12-22→ Common Stock (16,667 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-01-21−45,000→ 0 totalExercise: $2.16Exp: 2031-04-01→ Common Stock (45,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-01-21−3,643→ 0 totalExercise: $28.76Exp: 2028-11-01→ Common Stock (3,643 underlying) - Award
Stock Option (Right to Buy)
2025-01-21+3,643→ 3,643 totalExercise: $1.26Exp: 2028-11-01→ Common Stock (3,643 underlying) - Award
Stock Option (Right to Buy)
2025-01-21+16,667→ 16,667 totalExercise: $1.26Exp: 2030-12-22→ Common Stock (16,667 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-01-21−3,643→ 0 totalExercise: $33.43Exp: 2029-11-01→ Common Stock (3,643 underlying) - Award
Stock Option (Right to Buy)
2025-01-21+35,000→ 35,000 totalExercise: $1.26Exp: 2030-03-01→ Common Stock (35,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-01-21−3,643→ 0 totalExercise: $13.86Exp: 2027-11-01→ Common Stock (3,643 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-01-21−20,834→ 0 totalExercise: $6.42Exp: 2029-03-07→ Common Stock (20,834 underlying) - Award
Stock Option (Right to Buy)
2025-01-21+3,643→ 3,643 totalExercise: $1.26Exp: 2029-11-01→ Common Stock (3,643 underlying) - Award
Stock Option (Right to Buy)
2025-01-21+45,000→ 45,000 totalExercise: $1.26Exp: 2031-04-01→ Common Stock (45,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-01-21−3,643→ 0 totalExercise: $13.86Exp: 2025-11-01→ Common Stock (3,643 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-01-21−3,643→ 0 totalExercise: $13.86Exp: 2026-11-01→ Common Stock (3,643 underlying) - Award
Stock Option (Right to Buy)
2025-01-21+3,643→ 3,643 totalExercise: $1.26Exp: 2027-11-01→ Common Stock (3,643 underlying) - Award
Stock Option (Right to Buy)
2025-01-21+20,834→ 20,834 totalExercise: $1.26Exp: 2029-03-07→ Common Stock (20,834 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-01-21−35,000→ 0 totalExercise: $4.44Exp: 2030-03-01→ Common Stock (35,000 underlying)
Footnotes (3)
- [F1]The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023.
- [F2]The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- [F3]This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Documents
Issuer
Inhibikase Therapeutics, Inc.
CIK 0001750149
Entity typeother
Related Parties
1- filerCIK 0001827621
Filing Metadata
- Form type
- 4
- Filed
- Jan 21, 7:00 PM ET
- Accepted
- Jan 22, 4:05 PM ET
- Size
- 43.7 KB